Metagenomi Appoints Laurence Reid to Board of Directors

Metagenomi has appointed Laurence Reid, PhD, to its Board of Directors. Reid brings 30 years of experience in building biotech companies and shaping pipeline and business strategy. He has a track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth. Reid will support the team in advancing its innovative pipeline and building a world-class, science-driven company.

Metagenomi, Inc. (NASDAQ: MGX), a precision genetic medicines company, has appointed Dr. Laurence Reid, PhD, to its Board of Directors. Dr. Reid brings 30 years of experience in building biotech companies and shaping pipeline and business strategy. He is known for his deep expertise in business development, research and development strategy, and organizational growth.

Dr. Reid currently serves as the chairperson of Broken String Biosciences Ltd. and holds board positions at KalVista Pharmaceuticals (NASDAQ: KALV) and other private biotech firms. His previous roles include CEO positions at Decibel Therapeutics, which was acquired by Regeneron in 2023, and Warp Drive Bio, which merged with Revolution Medicines in 2018. He has also held leadership positions at Alnylam Pharmaceuticals and Millennium Pharmaceuticals.

“We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “Laurence’s insight and counsel will be invaluable as we continue to advance our proprietary gene editing technologies into the clinic and deliver on our vision to harness the power of metagenomics to create curative genetic medicines for patients.”

“I’m honored to join Metagenomi’s Board of Directors at such a pivotal time in the Company’s evolution. Metagenomi’s powerful gene editing platform is rooted in scientific rigor and has the potential to redefine the treatment landscape for patients suffering from serious genetic diseases,” said Dr. Reid. “I’m thrilled to support the team in advancing its innovative pipeline and building a world-class, science-driven company.”

Dr. Reid's appointment follows Metagenomi's recent advancements in its gene editing platform, which has analyzed over 7.4 billion proteins and has the potential to target any type of genetic mutation across the entire human genome. The company's lead development program in Hemophilia A is a potentially curative therapy designed to provide life-long protection from bleeding events and joint damage in adults and children.

Metagenomi's appointment of Dr. Reid underscores its commitment to leveraging scientific rigor and innovative platforms to create curative genetic medicines. With Dr. Reid's extensive experience in building biotech companies, Metagenomi aims to build a world-class, science-driven company that delivers on its vision to harness the power of metagenomics.

[1] https://www.stocktitan.net/news/MGX/metagenomi-appoints-laurence-reid-ph-d-to-its-board-of-a1i8urw8un4f.html
[2] https://www.ainvest.com/news/genmab-2025-earnings-surge-strategic-pipeline-momentum-position-high-growth-biotech-play-2508/